Back to Journals » Open Access Rheumatology: Research and Reviews » Volume 10

Impact of pegloticase on patient outcomes in refractory gout: current perspectives

Authors Cunha RN, Aguiar R, Farinha F

Received 2 July 2018

Accepted for publication 17 August 2018

Published 18 October 2018 Volume 2018:10 Pages 141—149


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Professor Chuan-Ju Liu

Rita N Cunha,1 Renata Aguiar,1 Filipa Farinha2

1Rheumatology Department, Centro Hospitalar do Baixo Vouga, Aveiro, Portugal; 2Centre for Rheumatology, University College London, London, UK

Abstract: Gout is currently the most frequent cause of inflammatory arthritis worldwide and is responsible for poor health-related quality of life and loss of work productivity. It is caused by high levels of serum urate, leading to the deposition of monosodium urate crystals in joints and soft tissues. This condition is associated with acute flares and, if untreated or refractory, chronic and potentially destructive arthritis and tophi formation. Pegloticase is a recombinant, pegylated uricase used in the treatment of gout patients who fail conventional urate-lowering therapy. In this review, we discuss the impact of pegloticase on patient outcomes in refractory gout. We analyze different parameters, such as plasma uric acid concentration, frequency of flares, tophi reduction, pain, function, quality of life, and safety.

Keywords: gout, urate-lowering therapy, pegloticase, patient outcomes

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]